These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8672727)

  • 21. Substituted carboranes and polyhedral hydroborate salts as anti-neoplastics.
    Hall IH; Elkins A; Powell WJ; Karthikeyan S; Sood A; Spielvogel BF
    Anticancer Res; 1998; 18(4A):2617-22. PubMed ID: 9703918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxicity and mode of action of 1-(1-cyclohexenyl) and 1-unsubstituted 3,5-pyrazolidinediones in human Molt4 T cell leukemia.
    Barnes BJ; Izydore RA; Hall IH
    Anticancer Res; 2001; 21(3B):1857-68. PubMed ID: 11497269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New antitumor imidazole derivative, 5-carbamoyl-1H-imidazol-4-yl piperonylate, as an inhibitor of purine synthesis and its activation by adenine phosphoribosyltransferase.
    Fukui M; Inaba M; Tsukagoshi S; Sakurai Y
    Cancer Res; 1982 Mar; 42(3):1098-102. PubMed ID: 6120758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function.
    Bronder JL; Moran RG
    Cancer Res; 2002 Sep; 62(18):5236-41. PubMed ID: 12234990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antifolates induce primary inhibition of the de novo purine pathway prior to 5-aminoimidazole-4-carboxamide ribotide transformylase in leukemia cells.
    Lyons SD; Christopherson RI
    Biochem Int; 1991 May; 24(1):187-97. PubMed ID: 1768258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cytotoxicity and mode of action of 2,3,4-trisubstituted pyrroles and related derivatives in human Tmolt4 leukemia cells.
    Gupton JT; Burham BS; Byrd BD; Krumpe KE; Stokes C; Shuford J; Winkle S; Webb T; Warren AE; Barnes CR; Henry J; Hall IH
    Pharmazie; 1999 Sep; 54(9):691-7. PubMed ID: 10522273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increase in thermosensitivity of tumor cells by lowering intracellular pH.
    Song CW; Lyons JC; Griffin RJ; Makepeace CM; Cragoe EJ
    Cancer Res; 1993 Apr; 53(7):1599-601. PubMed ID: 8384080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytotoxicity and mode of action of aliphatic dicarboxylic acids in L1210 lymphocytic leukemia cells.
    Hall IH; Izydore RA; Warren AE; Barnes CR
    Anticancer Res; 1999; 19(1A):205-11. PubMed ID: 10226544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of genkwadaphnin and gnidilatidin on the growth of P-388, L-1210 leukemia and KB carcinoma cells in vitro.
    Hall IH; Liou YF; Oswald CB; Lee KH
    Eur J Cancer Clin Oncol; 1986 Jan; 22(1):45-52. PubMed ID: 3754212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Substituted 4-hydroxyproline di- and tri-peptides as cytotoxic agents.
    Hall IH; Chen SY
    Amino Acids; 1999; 16(1):79-89. PubMed ID: 10078336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro.
    Perchellet EM; Magill MJ; Huang X; Dalke DM; Hua DH; Perchellet JP
    Anticancer Drugs; 2000 Jun; 11(5):339-52. PubMed ID: 10912950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
    Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
    Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Boron substituted deoxyribonucleosides as cytotoxic agents.
    Hall IH; Elkins A; Sood A; Tomasz J; SpielVogel BF
    Anticancer Res; 1996; 16(6B):3709-14. PubMed ID: 9042245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of N-hydroxy-N'-aminoguanidine isoquinoline in combination with other inhibitors of ribonucleotide reductase on L1210 cells.
    Weckbecker G; Weckbecker A; Lien EJ; Cory JG
    J Natl Cancer Inst; 1988 Jun; 80(7):491-6. PubMed ID: 2452889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity.
    Hamelink C; Hampson A; Wink DA; Eiden LE; Eskay RL
    J Pharmacol Exp Ther; 2005 Aug; 314(2):780-8. PubMed ID: 15878999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The anti-neoplastic activity of 2,3-dihydrophthalazine-1,4-dione and N-butyl-2,3-dihydrophthalazine-1,4-dione in human and murine tumor cells.
    Hall IH; Hall ES; Wong OT
    Anticancer Drugs; 1992 Feb; 3(1):55-62. PubMed ID: 1623217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumor effect of dithiole compounds.
    Yoshida E; Fukami T; Takamiya K; Okura A
    Anticancer Drug Des; 1988 Aug; 3(2):129-32. PubMed ID: 3408549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant oxygen metabolism in neoplastic cells injured by cytotoxic macrophages.
    Granger DL; Lehninger AL; Hibbs JB
    Adv Exp Med Biol; 1985; 184():51-63. PubMed ID: 4036709
    [No Abstract]   [Full Text] [Related]  

  • 39. Studies on the mechanism of 3-deazaguanine cytotoxicity in L1210-sensitive and -resistant cell lines.
    Singh G; Luna MK; Ardalan B
    Cancer Chemother Pharmacol; 1988; 22(3):191-6. PubMed ID: 2900700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Further studies on the pharmacologic effects of the 7-hydroxy catabolite of methotrexate in the L1210 murine leukemia cell.
    Seither RL; Rape TJ; Goldman ID
    Biochem Pharmacol; 1989 Mar; 38(5):815-22. PubMed ID: 2467676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.